You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an alternative browser.
You should upgrade or use an alternative browser.
Nanoemulsion Kills Highly Resistant Bacteria Found in Patients With Cystic Fibrosis
M
Mommafirst
Guest
<div class="FTQUOTE"><begin quote><i>Originally posted by: <b>laulau555</b></i>
I was telling my Mom about this and it turns out when I was younger we signed a release form saying my spudum could be sent to the University of Michigan for research, so my spudum may have been involved in this research =O</end quote></div>
How cool!! Its great to know that participation in these studies lead to real discoveries!!
I was telling my Mom about this and it turns out when I was younger we signed a release form saying my spudum could be sent to the University of Michigan for research, so my spudum may have been involved in this research =O</end quote></div>
How cool!! Its great to know that participation in these studies lead to real discoveries!!
M
Mommafirst
Guest
<div class="FTQUOTE"><begin quote><i>Originally posted by: <b>laulau555</b></i>
I was telling my Mom about this and it turns out when I was younger we signed a release form saying my spudum could be sent to the University of Michigan for research, so my spudum may have been involved in this research =O</end quote></div>
How cool!! Its great to know that participation in these studies lead to real discoveries!!
I was telling my Mom about this and it turns out when I was younger we signed a release form saying my spudum could be sent to the University of Michigan for research, so my spudum may have been involved in this research =O</end quote></div>
How cool!! Its great to know that participation in these studies lead to real discoveries!!
M
Mommafirst
Guest
<div class="FTQUOTE"><begin quote><i>Originally posted by: <b>laulau555</b></i>
I was telling my Mom about this and it turns out when I was younger we signed a release form saying my spudum could be sent to the University of Michigan for research, so my spudum may have been involved in this research =O</end quote></div>
How cool!! Its great to know that participation in these studies lead to real discoveries!!
I was telling my Mom about this and it turns out when I was younger we signed a release form saying my spudum could be sent to the University of Michigan for research, so my spudum may have been involved in this research =O</end quote></div>
How cool!! Its great to know that participation in these studies lead to real discoveries!!
M
Mommafirst
Guest
<div class="FTQUOTE"><begin quote><i>Originally posted by: <b>laulau555</b></i>
I was telling my Mom about this and it turns out when I was younger we signed a release form saying my spudum could be sent to the University of Michigan for research, so my spudum may have been involved in this research =O</end quote>
How cool!! Its great to know that participation in these studies lead to real discoveries!!
I was telling my Mom about this and it turns out when I was younger we signed a release form saying my spudum could be sent to the University of Michigan for research, so my spudum may have been involved in this research =O</end quote>
How cool!! Its great to know that participation in these studies lead to real discoveries!!
M
Mommafirst
Guest
<div class="FTQUOTE"><begin quote><i>Originally posted by: <b>laulau555</b></i>
<br />
<br />I was telling my Mom about this and it turns out when I was younger we signed a release form saying my spudum could be sent to the University of Michigan for research, so my spudum may have been involved in this research =O</end quote>
<br />
<br />How cool!! Its great to know that participation in these studies lead to real discoveries!!
<br />
<br />
<br />
<br />I was telling my Mom about this and it turns out when I was younger we signed a release form saying my spudum could be sent to the University of Michigan for research, so my spudum may have been involved in this research =O</end quote>
<br />
<br />How cool!! Its great to know that participation in these studies lead to real discoveries!!
<br />
<br />
Dear Katie,
First of all, please know that my associates at NanoBio join me in
desiring the very best for your daughters' progress. In regard your
inquiry, our technology employs high-energy, oil-in-water emulsions to
kill the targeted organism. In appearance and feel, a nanoemulsion is a
thin white liquid, very similar to skim milk. The unique aspect of
products derived from the company's NanoStat technology is that, unlike
currently available therapies, NanoBio's treatments are antibiotic free
and selectively toxic to microbes while non-irritating to skin and
mucous membranes:
<a target=_blank class=ftalternatingbarlinklarge href="http://www.nanobio.com/Platform-Technology/Mechanism-of-Action.html
">http://www.nanobio.com/Platfor...hanism-of-Action.html
</a>
As you may be aware, we are in the initial laboratory stages with the
development of our product for CF. We have yet to confirm that what we
see in the laboratory will be appropriate for use in man. Next steps in
the long development pathway and prior to initiation of a Phase I
clinical trial will be determined by results from additional laboratory
studies and FDA approval.
We have expectations that products that are in development by NanoBio as
well as several other organizations should make meaningful contributions
to the quality of life for CF patients. Treatment options have expanded
significantly over the last 30 years that I have been involved in the
medical industry and undoubtedly, progress will continue.
I will be happy to address other questions that you may have in the
future. In addition, more information on NanoBio and our drug
development programs are described on the NanoBio web site:
www.nanobio.com
Sincere best wishes,
John Coffey
____________________________
John F. Coffey, Jr.
Vice President Business Development
NanoBio Corporation
2311 Green Road, Suite A 48105
Ann Arbor, MI
www.nanobio.com
First of all, please know that my associates at NanoBio join me in
desiring the very best for your daughters' progress. In regard your
inquiry, our technology employs high-energy, oil-in-water emulsions to
kill the targeted organism. In appearance and feel, a nanoemulsion is a
thin white liquid, very similar to skim milk. The unique aspect of
products derived from the company's NanoStat technology is that, unlike
currently available therapies, NanoBio's treatments are antibiotic free
and selectively toxic to microbes while non-irritating to skin and
mucous membranes:
<a target=_blank class=ftalternatingbarlinklarge href="http://www.nanobio.com/Platform-Technology/Mechanism-of-Action.html
">http://www.nanobio.com/Platfor...hanism-of-Action.html
</a>
As you may be aware, we are in the initial laboratory stages with the
development of our product for CF. We have yet to confirm that what we
see in the laboratory will be appropriate for use in man. Next steps in
the long development pathway and prior to initiation of a Phase I
clinical trial will be determined by results from additional laboratory
studies and FDA approval.
We have expectations that products that are in development by NanoBio as
well as several other organizations should make meaningful contributions
to the quality of life for CF patients. Treatment options have expanded
significantly over the last 30 years that I have been involved in the
medical industry and undoubtedly, progress will continue.
I will be happy to address other questions that you may have in the
future. In addition, more information on NanoBio and our drug
development programs are described on the NanoBio web site:
www.nanobio.com
Sincere best wishes,
John Coffey
____________________________
John F. Coffey, Jr.
Vice President Business Development
NanoBio Corporation
2311 Green Road, Suite A 48105
Ann Arbor, MI
www.nanobio.com
Dear Katie,
First of all, please know that my associates at NanoBio join me in
desiring the very best for your daughters' progress. In regard your
inquiry, our technology employs high-energy, oil-in-water emulsions to
kill the targeted organism. In appearance and feel, a nanoemulsion is a
thin white liquid, very similar to skim milk. The unique aspect of
products derived from the company's NanoStat technology is that, unlike
currently available therapies, NanoBio's treatments are antibiotic free
and selectively toxic to microbes while non-irritating to skin and
mucous membranes:
<a target=_blank class=ftalternatingbarlinklarge href="http://www.nanobio.com/Platform-Technology/Mechanism-of-Action.html
">http://www.nanobio.com/Platfor...hanism-of-Action.html
</a>
As you may be aware, we are in the initial laboratory stages with the
development of our product for CF. We have yet to confirm that what we
see in the laboratory will be appropriate for use in man. Next steps in
the long development pathway and prior to initiation of a Phase I
clinical trial will be determined by results from additional laboratory
studies and FDA approval.
We have expectations that products that are in development by NanoBio as
well as several other organizations should make meaningful contributions
to the quality of life for CF patients. Treatment options have expanded
significantly over the last 30 years that I have been involved in the
medical industry and undoubtedly, progress will continue.
I will be happy to address other questions that you may have in the
future. In addition, more information on NanoBio and our drug
development programs are described on the NanoBio web site:
www.nanobio.com
Sincere best wishes,
John Coffey
____________________________
John F. Coffey, Jr.
Vice President Business Development
NanoBio Corporation
2311 Green Road, Suite A 48105
Ann Arbor, MI
www.nanobio.com
First of all, please know that my associates at NanoBio join me in
desiring the very best for your daughters' progress. In regard your
inquiry, our technology employs high-energy, oil-in-water emulsions to
kill the targeted organism. In appearance and feel, a nanoemulsion is a
thin white liquid, very similar to skim milk. The unique aspect of
products derived from the company's NanoStat technology is that, unlike
currently available therapies, NanoBio's treatments are antibiotic free
and selectively toxic to microbes while non-irritating to skin and
mucous membranes:
<a target=_blank class=ftalternatingbarlinklarge href="http://www.nanobio.com/Platform-Technology/Mechanism-of-Action.html
">http://www.nanobio.com/Platfor...hanism-of-Action.html
</a>
As you may be aware, we are in the initial laboratory stages with the
development of our product for CF. We have yet to confirm that what we
see in the laboratory will be appropriate for use in man. Next steps in
the long development pathway and prior to initiation of a Phase I
clinical trial will be determined by results from additional laboratory
studies and FDA approval.
We have expectations that products that are in development by NanoBio as
well as several other organizations should make meaningful contributions
to the quality of life for CF patients. Treatment options have expanded
significantly over the last 30 years that I have been involved in the
medical industry and undoubtedly, progress will continue.
I will be happy to address other questions that you may have in the
future. In addition, more information on NanoBio and our drug
development programs are described on the NanoBio web site:
www.nanobio.com
Sincere best wishes,
John Coffey
____________________________
John F. Coffey, Jr.
Vice President Business Development
NanoBio Corporation
2311 Green Road, Suite A 48105
Ann Arbor, MI
www.nanobio.com
Dear Katie,
First of all, please know that my associates at NanoBio join me in
desiring the very best for your daughters' progress. In regard your
inquiry, our technology employs high-energy, oil-in-water emulsions to
kill the targeted organism. In appearance and feel, a nanoemulsion is a
thin white liquid, very similar to skim milk. The unique aspect of
products derived from the company's NanoStat technology is that, unlike
currently available therapies, NanoBio's treatments are antibiotic free
and selectively toxic to microbes while non-irritating to skin and
mucous membranes:
<a target=_blank class=ftalternatingbarlinklarge href="http://www.nanobio.com/Platform-Technology/Mechanism-of-Action.html
">http://www.nanobio.com/Platfor...hanism-of-Action.html
</a>
As you may be aware, we are in the initial laboratory stages with the
development of our product for CF. We have yet to confirm that what we
see in the laboratory will be appropriate for use in man. Next steps in
the long development pathway and prior to initiation of a Phase I
clinical trial will be determined by results from additional laboratory
studies and FDA approval.
We have expectations that products that are in development by NanoBio as
well as several other organizations should make meaningful contributions
to the quality of life for CF patients. Treatment options have expanded
significantly over the last 30 years that I have been involved in the
medical industry and undoubtedly, progress will continue.
I will be happy to address other questions that you may have in the
future. In addition, more information on NanoBio and our drug
development programs are described on the NanoBio web site:
www.nanobio.com
Sincere best wishes,
John Coffey
____________________________
John F. Coffey, Jr.
Vice President Business Development
NanoBio Corporation
2311 Green Road, Suite A 48105
Ann Arbor, MI
www.nanobio.com
First of all, please know that my associates at NanoBio join me in
desiring the very best for your daughters' progress. In regard your
inquiry, our technology employs high-energy, oil-in-water emulsions to
kill the targeted organism. In appearance and feel, a nanoemulsion is a
thin white liquid, very similar to skim milk. The unique aspect of
products derived from the company's NanoStat technology is that, unlike
currently available therapies, NanoBio's treatments are antibiotic free
and selectively toxic to microbes while non-irritating to skin and
mucous membranes:
<a target=_blank class=ftalternatingbarlinklarge href="http://www.nanobio.com/Platform-Technology/Mechanism-of-Action.html
">http://www.nanobio.com/Platfor...hanism-of-Action.html
</a>
As you may be aware, we are in the initial laboratory stages with the
development of our product for CF. We have yet to confirm that what we
see in the laboratory will be appropriate for use in man. Next steps in
the long development pathway and prior to initiation of a Phase I
clinical trial will be determined by results from additional laboratory
studies and FDA approval.
We have expectations that products that are in development by NanoBio as
well as several other organizations should make meaningful contributions
to the quality of life for CF patients. Treatment options have expanded
significantly over the last 30 years that I have been involved in the
medical industry and undoubtedly, progress will continue.
I will be happy to address other questions that you may have in the
future. In addition, more information on NanoBio and our drug
development programs are described on the NanoBio web site:
www.nanobio.com
Sincere best wishes,
John Coffey
____________________________
John F. Coffey, Jr.
Vice President Business Development
NanoBio Corporation
2311 Green Road, Suite A 48105
Ann Arbor, MI
www.nanobio.com
Dear Katie,
First of all, please know that my associates at NanoBio join me in
desiring the very best for your daughters' progress. In regard your
inquiry, our technology employs high-energy, oil-in-water emulsions to
kill the targeted organism. In appearance and feel, a nanoemulsion is a
thin white liquid, very similar to skim milk. The unique aspect of
products derived from the company's NanoStat technology is that, unlike
currently available therapies, NanoBio's treatments are antibiotic free
and selectively toxic to microbes while non-irritating to skin and
mucous membranes:
<a target=_blank class=ftalternatingbarlinklarge href="http://www.nanobio.com/Platform-Technology/Mechanism-of-Action.html
">http://www.nanobio.com/Platfor...hanism-of-Action.html
</a>
As you may be aware, we are in the initial laboratory stages with the
development of our product for CF. We have yet to confirm that what we
see in the laboratory will be appropriate for use in man. Next steps in
the long development pathway and prior to initiation of a Phase I
clinical trial will be determined by results from additional laboratory
studies and FDA approval.
We have expectations that products that are in development by NanoBio as
well as several other organizations should make meaningful contributions
to the quality of life for CF patients. Treatment options have expanded
significantly over the last 30 years that I have been involved in the
medical industry and undoubtedly, progress will continue.
I will be happy to address other questions that you may have in the
future. In addition, more information on NanoBio and our drug
development programs are described on the NanoBio web site:
www.nanobio.com
Sincere best wishes,
John Coffey
____________________________
John F. Coffey, Jr.
Vice President Business Development
NanoBio Corporation
2311 Green Road, Suite A 48105
Ann Arbor, MI
www.nanobio.com
First of all, please know that my associates at NanoBio join me in
desiring the very best for your daughters' progress. In regard your
inquiry, our technology employs high-energy, oil-in-water emulsions to
kill the targeted organism. In appearance and feel, a nanoemulsion is a
thin white liquid, very similar to skim milk. The unique aspect of
products derived from the company's NanoStat technology is that, unlike
currently available therapies, NanoBio's treatments are antibiotic free
and selectively toxic to microbes while non-irritating to skin and
mucous membranes:
<a target=_blank class=ftalternatingbarlinklarge href="http://www.nanobio.com/Platform-Technology/Mechanism-of-Action.html
">http://www.nanobio.com/Platfor...hanism-of-Action.html
</a>
As you may be aware, we are in the initial laboratory stages with the
development of our product for CF. We have yet to confirm that what we
see in the laboratory will be appropriate for use in man. Next steps in
the long development pathway and prior to initiation of a Phase I
clinical trial will be determined by results from additional laboratory
studies and FDA approval.
We have expectations that products that are in development by NanoBio as
well as several other organizations should make meaningful contributions
to the quality of life for CF patients. Treatment options have expanded
significantly over the last 30 years that I have been involved in the
medical industry and undoubtedly, progress will continue.
I will be happy to address other questions that you may have in the
future. In addition, more information on NanoBio and our drug
development programs are described on the NanoBio web site:
www.nanobio.com
Sincere best wishes,
John Coffey
____________________________
John F. Coffey, Jr.
Vice President Business Development
NanoBio Corporation
2311 Green Road, Suite A 48105
Ann Arbor, MI
www.nanobio.com
Dear Katie,
<br />
<br />First of all, please know that my associates at NanoBio join me in
<br />desiring the very best for your daughters' progress. In regard your
<br />inquiry, our technology employs high-energy, oil-in-water emulsions to
<br />kill the targeted organism. In appearance and feel, a nanoemulsion is a
<br />thin white liquid, very similar to skim milk. The unique aspect of
<br />products derived from the company's NanoStat technology is that, unlike
<br />currently available therapies, NanoBio's treatments are antibiotic free
<br />and selectively toxic to microbes while non-irritating to skin and
<br />mucous membranes:
<br /><a target=_blank class=ftalternatingbarlinklarge href="http://www.nanobio.com/Platform-Technology/Mechanism-of-Action.html
">http://www.nanobio.com/Platfor...hanism-of-Action.html
</a><br />
<br />As you may be aware, we are in the initial laboratory stages with the
<br />development of our product for CF. We have yet to confirm that what we
<br />see in the laboratory will be appropriate for use in man. Next steps in
<br />the long development pathway and prior to initiation of a Phase I
<br />clinical trial will be determined by results from additional laboratory
<br />studies and FDA approval.
<br />
<br />We have expectations that products that are in development by NanoBio as
<br />well as several other organizations should make meaningful contributions
<br />to the quality of life for CF patients. Treatment options have expanded
<br />significantly over the last 30 years that I have been involved in the
<br />medical industry and undoubtedly, progress will continue.
<br />
<br />I will be happy to address other questions that you may have in the
<br />future. In addition, more information on NanoBio and our drug
<br />development programs are described on the NanoBio web site:
<br />www.nanobio.com
<br />
<br />Sincere best wishes,
<br />
<br />John Coffey
<br />
<br />____________________________
<br />
<br />John F. Coffey, Jr.
<br />Vice President Business Development
<br />NanoBio Corporation
<br />2311 Green Road, Suite A 48105
<br />Ann Arbor, MI
<br />www.nanobio.com
<br />
<br />First of all, please know that my associates at NanoBio join me in
<br />desiring the very best for your daughters' progress. In regard your
<br />inquiry, our technology employs high-energy, oil-in-water emulsions to
<br />kill the targeted organism. In appearance and feel, a nanoemulsion is a
<br />thin white liquid, very similar to skim milk. The unique aspect of
<br />products derived from the company's NanoStat technology is that, unlike
<br />currently available therapies, NanoBio's treatments are antibiotic free
<br />and selectively toxic to microbes while non-irritating to skin and
<br />mucous membranes:
<br /><a target=_blank class=ftalternatingbarlinklarge href="http://www.nanobio.com/Platform-Technology/Mechanism-of-Action.html
">http://www.nanobio.com/Platfor...hanism-of-Action.html
</a><br />
<br />As you may be aware, we are in the initial laboratory stages with the
<br />development of our product for CF. We have yet to confirm that what we
<br />see in the laboratory will be appropriate for use in man. Next steps in
<br />the long development pathway and prior to initiation of a Phase I
<br />clinical trial will be determined by results from additional laboratory
<br />studies and FDA approval.
<br />
<br />We have expectations that products that are in development by NanoBio as
<br />well as several other organizations should make meaningful contributions
<br />to the quality of life for CF patients. Treatment options have expanded
<br />significantly over the last 30 years that I have been involved in the
<br />medical industry and undoubtedly, progress will continue.
<br />
<br />I will be happy to address other questions that you may have in the
<br />future. In addition, more information on NanoBio and our drug
<br />development programs are described on the NanoBio web site:
<br />www.nanobio.com
<br />
<br />Sincere best wishes,
<br />
<br />John Coffey
<br />
<br />____________________________
<br />
<br />John F. Coffey, Jr.
<br />Vice President Business Development
<br />NanoBio Corporation
<br />2311 Green Road, Suite A 48105
<br />Ann Arbor, MI
<br />www.nanobio.com